Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hoos, 2016, Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations, Nat Rev Drug Discov., 15, 235, 10.1038/nrd.2015.35
Ott, 2017, An immunogenic personal neoantigen vaccine for patients with melanoma, Nature, 547, 217, 10.1038/nature22991
Mitchison, 1955, Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer, J Exp Med., 102, 157, 10.1084/jem.102.2.157
Hedrick, 1993, Chimeric T cell receptor-immunoglobulin molecules: function and applications, Int Rev Immunol, 10, 279, 10.3109/08830189309061702
Rosenbaum, 2017, Tragedy, perseverance, and chance - the story of CAR-T therapy, N Engl J Med., 377, 1313, 10.1056/NEJMp1711886
Yang, 2015, Cancer immunotherapy: harnessing the immune system to battle cancer, J Clin Invest., 125, 3335, 10.1172/JCI83871
Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med., 3, 95ra73, 10.1126/scitranslmed.3002842
Sadelain, 2009, The promise and potential pitfalls of chimeric antigen receptors, Curr Opin Immunol., 21, 215, 10.1016/j.coi.2009.02.009
Maher, 2002, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor, Nat Biotechnol., 20, 70, 10.1038/nbt0102-70
Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified t cells after failure of ibrutinib, J Clin Oncol., 35, 3010, 10.1200/JCO.2017.72.8519
Locke, 2017, Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma, Mol Ther., 25, 285, 10.1016/j.ymthe.2016.10.020
Tang, 2016, Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol, BMJ Open, 6, e013904, 10.1136/bmjopen-2016-013904
Porter, 2015, Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med., 7, 303ra139, 10.1126/scitranslmed.aac5415
Ali, 2016, T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, Blood, 128, 1688, 10.1182/blood-2016-04-711903
Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med., 378, 449, 10.1056/NEJMoa1709919
Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med., 378, 439, 10.1056/NEJMoa1709866
Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447
Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in Relapsed or refractory multiple myeloma, N Engl J Med., 380, 1726, 10.1056/NEJMoa1817226
Abramson, 2018, High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration, J Clin Oncol, 36, 120, 10.1200/JCO.2018.36.5_suppl.120
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med., 371, 1507, 10.1056/NEJMoa1407222
Mueller, 2017, Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, Blood, 130, 2317, 10.1182/blood-2017-06-786129
Mueller, 2018, Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia, Clin Cancer Res, 24, 6175, 10.1158/1078-0432.CCR-18-0758
Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med., 6, 224ra25, 10.1126/scitranslmed.3008226
Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Li, 2019, CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity, Sci Transl Med., 11, eaax8861, 10.1126/scitranslmed.aax8861
Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov., 7, 1404, 10.1158/2159-8290.CD-17-0698
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Park, 2016, CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date, Blood, 127, 3312, 10.1182/blood-2016-02-629063
Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med., 380, 45, 10.1056/NEJMoa1804980
Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest., 126, 2123, 10.1172/JCI85309
Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat Med., 24, 563, 10.1038/s41591-018-0010-1
Siegel, 2011, A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory, Immunity, 35, 806, 10.1016/j.immuni.2011.09.016
Chou, 2013, T cell replicative senescence in human aging, Curr Pharm Des., 19, 1680, 10.2174/138161213805219711
Wherry, 2015, Molecular and cellular insights into T cell exhaustion, Nat Rev Immunol., 15, 486, 10.1038/nri3862
Maude, 2016, Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL, J Clin Oncol., 34, 3007, 10.1200/JCO.2016.34.15_suppl.3007
Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838
Yang, 2017, TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance, Sci Transl Med, 9, eaag1209, 10.1126/scitranslmed.aag1209
Gardner, 2017, Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208
Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 20, 31, 10.1016/s1470-2045(18)30864-7
Rosenthal, 2018, Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia, Am J Hematol., 93, E352, 10.1002/ajh.25235
Sotillo, 2015, Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov., 5, 1282, 10.1158/2159-8290.CD-15-1020
Orlando, 2018, Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat Med, 24, 1504, 10.1038/s41591-018-0146-z
Stass, 1984, Lineage switch in acute leukemia, Blood, 64, 701, 10.1182/blood.V64.3.701.bloodjournal643701
Jacoby, 2016, CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity, Nat Commun., 7, 12320, 10.1038/ncomms12320
Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547
Dorantes-Acosta, 2012, Lineage switching in acute leukemias: a consequence of stem cell plasticity?, Bone Marrow Res., 2012, 406796, 10.1155/2012/406796
Braig, 2017, Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking, Blood, 129, 100, 10.1182/blood-2016-05-718395
Fry, 2018, CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat Med., 24, 20, 10.1038/nm.4441
Corazza, 2009, TRAIL-induced apoptosis: between tumor therapy and immunopathology, Ann N Y Acad Sci., 1171, 50, 10.1111/j.1749-6632.2009.04905.x
Platanias, 2013, Interferons and their antitumor properties, J Interferon Cytokine Res, 33, 143, 10.1089/jir.2013.0019
Torres-Collado, 2018, Overcoming resistance of human non-Hodgkin's lymphoma to CD19-CAR CTL therapy by celecoxib and histone deacetylase inhibitors, Cancers, 10, E200, 10.3390/cancers10060200
Peng, 2016, Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov., 6, 202, 10.1158/2159-8290.CD-15-0283
Jia, 2008, Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis, Nature., 454, 776, 10.1038/nature07091
Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med., 375, 819, 10.1056/NEJMoa1604958
Riaz, 2017, Tumor and microenvironment evolution during immunotherapy with nivolumab, Cell, 171, 934, 10.1016/j.cell.2017.09.028
Xu-Monette, 2018, PD-1 expression and clinical PD-1 blockade in B-cell lymphomas, Blood, 131, 68, 10.1182/blood-2017-07-740993
Fang, 2017, The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma, Medicine, 96, e6398, 10.1097/MD.0000000000006398
Goodman, 2017, PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas, Nat Rev Clin Oncol., 14, 203, 10.1038/nrclinonc.2016.168
Chen, 2018, Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response, Nature, 560, 382, 10.1038/s41586-018-0392-8
Fischer, 2007, Inhibitory effect of tumor cell-derived lactic acid on human T cells, Blood, 109, 3812, 10.1182/blood-2006-07-035972
Alfarouk, 2015, Erratum: glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question, Oncoscience., 2, 317, 10.18632/oncoscience.158
Gajewski, 2010, Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy, Cancer J., 16, 399, 10.1097/PPO.0b013e3181eacbd8
Joyce, 2015, T cell exclusion, immune privilege, and the tumor microenvironment, Science, 348, 74, 10.1126/science.aaa6204
Mehta, 2018, Immunotherapy resistance by inflammation-induced dedifferentiation, Cancer Discov., 8, 935, 10.1158/2159-8290.CD-17-1178
Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res., 12, 6106, 10.1158/1078-0432.CCR-06-1183
Maus, 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res., 1, 26, 10.1158/2326-6066.CIR-13-0006
Li, 2019, A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy, J Immunother Cancer., 7, 51, 10.1186/s40425-019-0529-9
Qasim, 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci Transl Med., 9, 10.1126/scitranslmed.aaj2013
Cho, 2018, Universal chimeric antigen receptors for multiplexed and logical control of T cell responses, Cell, 173, 1426, 10.1016/j.cell.2018.03.038
Salter, 2018, Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function, Sci Signal, 11, eaat6753, 10.1126/scisignal.aat6753
Zhao, 2015, Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004
Ramos, 2018, In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas, Mol Ther, 26, 2727, 10.1016/j.ymthe.2018.09.009
Enblad, 2018, A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia, Clin Cancer Res, 24, 6185, 10.1158/1078-0432.CCR-18-0426
Kueberuwa, 2017, CCR7(+) selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo, J Immunother Cancer., 5, 14, 10.1186/s40425-017-0216-7
Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z
Ruella, 2016, Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J Clin Invest., 126, 3814, 10.1172/JCI87366
Aleksic, 2012, Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies, Eur J Immunol., 42, 3174, 10.1002/eji.201242606
Caruso, 2015, Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity, Cancer Res., 75, 3505, 10.1158/0008-5472.CAN-15-0139
Chu, 2013, Innate immune recognition of the microbiota promotes host-microbial symbiosis, Nat Immunol., 14, 668, 10.1038/ni.2635
Matzinger, 1994, Tolerance, danger, and the extended family, Ann Rev Immunol., 12, 991, 10.1146/annurev.iy.12.040194.005015
Kroemer, 2013, Immunogenic cell death in cancer therapy, Ann Rev Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008
Obeid, 2007, Calreticulin exposure dictates the immunogenicity of cancer cell death, Nat Med., 13, 54, 10.1038/nm1523
Fucikova, 2011, Human tumor cells killed by anthracyclines induce a tumor-specific immune response, Cancer Res., 71, 4821, 10.1158/0008-5472.CAN-11-0950
Karlsson, 2013, Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy, Cancer Gene Ther., 20, 386, 10.1038/cgt.2013.35
Summers, 2018, Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission, Blood, 132, 967, 10.1182/blood-2018-99-115599
Chmielewski, 2015, TRUCKs: the fourth generation of CARs, Expert Opin Biol Ther., 15, 1145, 10.1517/14712598.2015.1046430